A Phase II, Randomized Trial of Standard of Care with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia

Trial Profile

A Phase II, Randomized Trial of Standard of Care with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Midostaurin (Primary) ; Antineoplastics
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms RADIUS
  • Sponsors Novartis
  • Most Recent Events

    • 27 Feb 2017 Planned End Date changed from 1 Mar 2018 to 31 Jul 2017.
    • 27 Feb 2017 Planned primary completion date changed from 1 Mar 2018 to 31 Jul 2017.
    • 06 Dec 2016 Preliminary safety results (n=56, data cutoff 3 Jun 2016) in the post-alloHSCT setting, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top